EN DE
Watch AC Immune Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AC Immune Ltd (ACIU) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of AC Immune Ltd stock $1.55, price $2.09, that is 25.8% below the price, quality 31 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Switzerland · ISIN CH0329023102

AI AC Immune Ltd logo Thin data Nov 10, 2026

AC Immune Ltd

ACIU · US

Expensive (fair value 26% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value $1.55 · Overvalued 
Quality 31/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −25.4 %/yr in CHF) 
Negative free cash flow 
Trails peers (3/8) 
Narrow moat 14/100 · thin data
Thin data 
Estimate
Watch AC Immune Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.13 $1.48 Fair Value $1.55 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.48 – $8.13 · fair‑value band $1.16 – $1.94 · the $2.09 price screens above the $1.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow AC Immune in your weekly email

Every Wednesday you see whether AC Immune is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Show moreShow less

The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases.

Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies.

Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.

AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Stock analysis

AC Immune Ltd (ACIU) currently trades at $2.09, while our estimate is $1.55, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.16 (bear) to $1.94 (bull), the price of $2.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

AC Immune Ltd reported revenue of CHF 3.6M in FY2025 versus CHF 944K in FY2021, a compound +39.5%/yr. Reported net income was −CHF 70.4M in FY2025.

Key figures

Market cap $206M Micro · P/S ratio 12.7 · EPS (TTM) $−0.4400 · Return on equity −78.5% · Return on assets (EBIT) −33.0% (5-year average) · Operating margin 7.9% · Revenue growth (YoY) +10.6% · Free cash flow −CHF 67.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, ACIU screens richer than that median.

Fair Value

Bear $1.16 Fair Value $1.55 Bull $1.94
Price $2.09 · Downside -25.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 21
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 48
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleAndrea PfeiferChief Executive Officer, Director2× since Apr 15, 2026: 20,000 shares, avg. $2.97$59,300May 15, 202610b5-1 plan

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−86.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.4%
Start year 2020 (pandemic). Over 10 years: −21.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−397.0% (2020) → −1,927.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ACIU screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare AC Immune Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Below median
Fair Value upside −25.8% · Below median
Profitability
Return on assets −45.6% · Below median
Operating margin (12 months) 7.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 10.6% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.85× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 9.88× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)53 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ACIU
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ACIU
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs ACIU
argenx SE ARGX $950.95 $908.40 −4% vs ACIU
CSL Limited CSL A$199.55 A$186.49 −7% vs ACIU
Moderna, Inc MRNA $215.27 $135.64 −37% vs ACIU
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs ACIU
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ACIU
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs ACIU
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ACIU

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AC Immune Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AC Immune Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ACIU

Frequently asked questions

Is AC Immune Ltd (ACIU) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.55 versus a price of $2.09, about 26% lower (overvalued).
What is the fair value of ACIU?
Our estimate for AC Immune Ltd is $1.55 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.09.
What is the quality score of ACIU?
AC Immune Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AC Immune Ltd (ACIU)?
Our calculated price target is the estimate of $1.55 (as of Nov 10, 2026). Cautious scenario $1.16, optimistic scenario $1.94. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AC Immune Ltd stock forecast for 2026?
Our estimate puts fair value at $1.55, about 26% lower versus a price of $2.09 (overvalued). Cautious scenario $1.16, optimistic scenario $1.94. The calculation is refreshed regularly with new filings.
What is the intrinsic value of AC Immune Ltd (ACIU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AC Immune Ltd it is $1.55 per share (as of Nov 10, 2026), against a price of $2.09.
Is AC Immune Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ACIU trades above its calculated fair value: price $2.09, fair value $1.55, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACIU?
No. The price is what the market pays today ($2.09); the fair value is what the company's own numbers justify ($1.55). For AC Immune Ltd the two are $0.5400 per share apart. That gap is exactly why we show both numbers side by side.
How much is AC Immune Ltd worth?
The market values AC Immune Ltd at about $206M (market capitalisation, as of Nov 10, 2026). Per share that is $2.09; our models calculate a fair value of $1.55 per share.
What do the bullish and bearish scenarios say about ACIU?
Our models span a range for AC Immune Ltd: cautious scenario $1.16, base $1.55, optimistic $1.94 per share (as of Nov 10, 2026, price $2.09). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AC Immune Ltd (ACIU)?
Balance-sheet figures for AC Immune Ltd (as of Nov 10, 2026): return on equity −78.5%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is ACIU from its 52-week high?
AC Immune Ltd trades at $2.09, about 44% below its 52-week high of $3.70 and 1% above the low of $2.06 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.55 is for.
Which stocks are comparable to AC Immune Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AC Immune Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price $2.09, calculated fair value $1.55 (−26%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. AC Immune Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AC Immune Ltd (ACIU)?
The closing price on Nov 16, 2026 was $2.09. Our estimate is $1.55, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AC Immune Ltd right now?
The price sits above even our optimistic bull case ($1.94). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of AC Immune Ltd

How large is the market capitalisation of AC Immune Ltd (ACIU)?
The market capitalisation of AC Immune Ltd is $206M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AC Immune Ltd (ACIU)?
The price-to-sales ratio of AC Immune Ltd is 12.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AC Immune Ltd (ACIU)?
Earnings per share at AC Immune Ltd are $−0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AC Immune Ltd (ACIU)?
The return on equity (ROE) of AC Immune Ltd is −78.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AC Immune Ltd (ACIU)?
On an EBIT basis the return on assets of AC Immune Ltd is −33.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AC Immune Ltd (ACIU)?
The operating margin of AC Immune Ltd is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AC Immune Ltd (ACIU)?
Revenue at AC Immune Ltd is growing 10.6% versus a year earlier (3y avg −3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AC Immune Ltd (ACIU) generate?
The free cash flow of AC Immune Ltd is −CHF 67.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AC Immune Ltd (ACIU) hold?
AC Immune Ltd holds more cash than debt, CHF 22.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AC Immune Ltd in the live analysis

One click puts AC Immune Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.